Your computer can help scientists search for new childhood cancer treatments

IBMMedical researchers and IBM (NYSE: IBM) are asking the public's help in finding prospective treatments for childhood cancers, the top worldwide cause of death by disease for children. Scientists are searching for chemical drug candidates that can affect the key molecules and proteins that control cancer cells in several common childhood cancers. However, finding drug candidates is an expensive and slow process.

To accelerate the process and broaden the search, IBM is providing those scientists free access to World Community Grid, an IBM-funded and managed program which advances scientific research by harnessing computing power "donated" by volunteers around the globe. This resource is the equivalent of a free, virtual supercomputer that enables scientists to more quickly conduct millions of virtual experiments to help pinpoint promising drug candidates for further study.

The project was announced in the United States at a press conference led by Connecticut Governor Dannel Malloy, IBM, and Dr. Ching Lau of Connecticut Children’s Medical Center, Jackson Laboratory and UConn School of Medicine, who is spearheading this crowdsourced research effort in the US.

Volunteers don't provide any time, money or technical expertise to assist with this research effort, called Smash Childhood Cancer. Instead, they participate in World Community Grid by downloading and installing a free, secure app on their computer or Android devices. While otherwise idle, volunteers' devices automatically perform virtual experiments on behalf of the research team. The results are transmitted back to researchers, where they are analyzed.

Smash Childhood Cancer brings together an international team of expert researchers from Chiba University and Kyoto University in Japan; The University of Hong Kong in Hong Kong; and the Connecticut Children's Medical Center, the Jackson Laboratory, and the University of Connecticut School of Medicine in the United States.

The global initiative is led by Dr. Akira Nakagawara, an internationally renowned pediatric oncologist, molecular biologist and CEO of the Saga Medical Center KOSEIKAN, in Japan. Dr. Nakagawara used the same research approach on a previous World Community Grid project which successfully identified drug candidates for neuroblastoma, one of the most common cancers in children.

Smash Childhood Cancer expands the search for treatments for neuroblastoma, as well as other forms of childhood cancers including brain tumor, Wilms’ tumor (tumor of the kidney), germ cell tumors (which impact the reproductive and central nervous system), hepatoblastoma (cancer of the liver) and osteosarcoma (cancer of the bone).

Since 2004, IBM’s award-winning World Community Grid has provided this resource for 27 research projects in critical areas including cancer, HIV/AIDS, Zika and Ebola viruses, genetic mapping, sustainable energy, clean water, and ecosystem preservation.

To date, World Community Grid has connected researchers to half a billion U.S. dollars' worth of free supercomputing power. This resource to accelerate scientific discovery, partially hosted in IBM's cloud, has been fueled by 720,000 individuals and 440 institutions from 80 countries who have have donated more than 1 million years of computing time on over 3 million desktops, laptops and Android mobile devices. Their participation has helped identify potential treatments for childhood cancer, more efficient solar cells, and more efficient water filtration materials.

World Community Grid is enabled by Berkeley Open Infrastructure for Network Computing (BOINC), an open source software platform developed at the University of California, Berkeley.

Join World Community Grid today to enable your computer or Android device to help Smash Childhood Cancer.

For further information, please visit:
https://www.worldcommunitygrid.org

Most Popular Now

Pfizer and Lilly announce top-line results from lo…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the stu...

Bristol-Myers Squibb reports first quarter financi…

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (a...

Walnuts may help lower blood pressure for those at…

When combined with a diet low in saturated fats, eating walnuts may help lower blood pressure in people at risk for cardiovascular disease, according to a new Penn State ...

Amgen ignites a social fitness movement to support…

Amgen (NASDAQ:AMGN) launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support t...

Comprehensive tumor profiling promises new therape…

The WINTHER trial, NCT01856296, led by investigators from Vall d'Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave...

AstraZeneca starts artificial intelligence collabo…

AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treat...

Possible link between autism and antidepressants u…

An international team led by Duke-NUS Medical School has found a potential link between autistic-like behaviour in adult mice and exposure to a common antidepressant in t...

Chemotherapy or not?

Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how "smart" diagnostic-imaging machi...

Researchers define Alzheimer's-like brain disorder

A brain disorder that mimics symptoms of Alzheimer's disease has been defined with recommended diagnostic criteria and guidelines for advancing future research on the con...

Drugs to prevent stroke and dementia show promise …

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study...

Amgen and Syapse enter precision medicine collabor…

Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precisio...

Personalizing precision medicine with combination …

Precision oncology often relies on treating patients with a single, molecularly matched therapy that targets one mutation in their tumor. In a report, published online in...